Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease [Yahoo! Finan...
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
For European and UK medical and trade media only For immediate release Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA ® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease Submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn's disease, which each achieved their primary endpoints Beerse, Belgium (May 01, 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing Authorisation Application for TREMFYA ® (guselkumab) to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease. The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn's disease. In the Phase
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Best San Diego Mesothelioma Lawyers Of 2024 [Forbes]Forbes
- Osteotec announces Lisa Watts as National Sales Manager of new spine division [Yahoo! Finance]Yahoo! Finance
- Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks [Yahoo! Finance]Yahoo! Finance
- Global Breast Implant Market Projected to Reach US$ 4.1 Billion by 2032 [Yahoo! Finance]Yahoo! Finance
- Wall Street Breakfast Podcast: Comcast Unveils StreamSaver Bundle [Seeking Alpha]Seeking Alpha
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 5/15/24 - Form 424B2
- 5/14/24 - Form FWP
- 5/14/24 - Form 424B5
- JNJ's page on the SEC website